Faeth Therapeutics (FTH) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed Keros Therapeutics (KROS) over the past year, losing 9.6% versus a loss of 36.3%. Over five years, KROS leads with a -80.2% price change compared with -95.0% for FTH. Keros Therapeutics is the larger company by market cap ($217.4 million vs $203.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | KROS |
|---|---|---|
| Share price | $7.88 | $11.08 |
| Market cap | $203.65M | $217.44M |
| 1-day change | -9.32% | -2.72% |
| YTD return | -26.15% | -45.58% |
| 1-year return | -9.64% | -36.29% |
| 5-year return | -94.96% | -80.25% |
| EPS (TTM) | $-22.50 | $-2.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $243.86M |
| Net income (latest FY) | $-21.09M | $87.01M |
| Operating margin | — | 27.71% |
| Net margin | — | 35.68% |
| 52-week high | $42.14 | $22.55 |
| 52-week low | $7.45 | $8.98 |
| Distance from 52-week high | -81.30% | -50.86% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +612.56% | +78.97% |
| Average volume | 500.25K | 196.50K |
| Shares outstanding | 25.84M | 19.62M |
| Employees | 29 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed KROS by 26.6 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
FTH vs KROS FAQ
Which is bigger, Faeth Therapeutics or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $217.44M compared with $203.65M for Faeth Therapeutics (FTH).
Which stock has performed better over the past year, FTH or KROS?
FTH returned -9.64% over the past 12 months, compared with -36.29% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.